AbbVie's Temab-A gets two FDA breakthrough designations
AbbVie says the U.S. FDA granted Telisotuzumab Adizutecan (Temab-A) breakthrough therapy designations for CRC and NSCLC.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.